Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection (GS-US-320-1092)
To find out the effects of tenofovir alafenamide (TAF) on children and adolescents with chronic hepatitis B.
To find out the effects of tenofovir alafenamide (TAF) on children and adolescents with chronic hepatitis B.
To assess the survival rate of subjects at 6 and 12 months following implantation of the Bioabsorbable pulmonary valve conduit. To assess the rate of conduit failures at 6 months, requiring re-intervention or reoperation.